RKO Xenograft Model Service for Colon Cancer

The RKO xenograft model offers a robust, genetically defined platform for evaluating therapeutic strategies in colon cancer preclinical research. Alfa Cytology provides validated RKO xenograft services, from model construction to endpoint analysis, ensuring reproducible data to accelerate your oncology drug development pipeline.

Overview of RKO Xenograft Model for Colon Cancer

The RKO cell line was established from a poorly differentiated human colorectal carcinoma and has become a cornerstone model in colon cancer research. Genetically, RKO is characterized by microsatellite instability-high (MSI-H) status, wild-type TP53, and the absence of common KRAS and BRAF mutations. It exhibits epigenetic silencing of MLH1, leading to deficient DNA mismatch repair, and expresses high levels of urokinase-type plasminogen activator receptor (u-PAR), which is linked to tumor invasion and extracellular matrix remodeling. These molecular features position RKO as a representative model of the CpG island methylator phenotype (CIMP) subtype of colorectal cancer.

In vivo, RKO cells form aggressive, well-engrafted tumors in immunodeficient murine hosts, including nude and NOD/SCID mice. The xenograft model reliably recapitulates histopathological features of poorly differentiated colorectal carcinoma and demonstrates pronounced sensitivity to DNA-damaging agents. Researchers have leveraged the RKO xenograft to investigate p53-mediated apoptosis, epigenetic regulation via DNA methyltransferase inhibitors, and combination therapeutic strategies. Its stable genomic profile and short doubling time make it particularly suitable for high-throughput drug screening, gene silencing studies, and mechanistic interrogation of treatment resistance in colon cancer.

Figure 1. Metformin inhibits RKO cell proliferation at high concentrations. (Park, Song Yi, et al., 2019)

Cell Line Information: RKO

The following table summarizes the essential characteristics of the RKO cell line:

Our Services

Alfa Cytology delivers comprehensive RKO xenograft model services tailored to your preclinical research objectives. Our experienced team handles every stage of the workflow---from cell line authentication and quality-controlled expansion to in vivo implantation, longitudinal tumor monitoring, and multi-endpoint histopathological and molecular analysis. We ensure strict adherence to IACUC guidelines and GLP-aligned protocols, providing you with reliable, publication-ready data to advance your colon cancer therapeutic programs.

Workflow of RKO Xenograft Model Construction

The construction of the RKO xenograft model follows a standardized, quality-controlled workflow designed to ensure reproducible tumor growth and robust data generation. The process begins with authenticated RKO cell culture and culminates in comprehensive tumor and tissue analysis at study endpoint.

1. Cell Line Authentication and Expansion: RKO cells are authenticated by STR profiling and expanded under sterile conditions in DMEM with 10% FBS. Cells are harvested at 70-80% confluency to ensure high viability and optimal tumorigenic potential.
2. Cell Preparation and Matrigel Suspension: Harvested cells are washed, counted, and resuspended in a 1:1 mixture of serum-free medium and Matrigel at a concentration of 1 x 10^7 cells/mL. The Matrigel matrix supports initial cell attachment and promotes rapid tumor engraftment.
3. Animal Preparation and Inoculation: Immunodeficient mice (e.g., athymic BALB/c nude or NOD/SCID, 6-10 weeks old) are acclimatized under pathogen-free conditions. A single subcutaneous injection of 1 x 10^6 cells (100 microL volume) is administered into the hind flank. Orthotopic models involve direct injection into the colonic wall under surgical guidance.
4. Tumor Establishment and Monitoring: Tumors are monitored by digital caliper measurement every 2-3 days. Tumor volume is calculated using the formula (length x width^2) / 2. Treatment typically initiates when tumors reach 50-150 mm^3. Body weights are recorded tri-weekly to assess general health.
5. Treatment Administration and Randomization: Once tumors are established, animals are randomized into treatment and control groups. Test compounds are administered via the specified route (oral gavage, intraperitoneal, or intravenous) according to the study protocol.
6. Endpoint Analysis and Tissue Collection: Studies conclude when tumors reach the institutional size limit (typically 2,000 mm^3) or at a predefined timepoint. Tumors are excised, weighed, and processed for histology (10% neutral buffered formalin), snap-freezing in liquid nitrogen, or stabilization in RNAlater for downstream molecular analysis.
7. Histopathological and Molecular Analysis: Resected tissues undergo H&E staining and immunohistochemistry (IHC) for markers such as Ki-67, cleaved caspase-3, and CD31. Molecular profiling includes RT-qPCR, Western blotting, and proteomic analysis to characterize therapeutic responses and mechanism of action.

Figure 2: Schematic workflow illustrating the derivation and construction of the RKO Xenograft Model at Alfa Cytology.

Case Study-RKO Xenograft Model Development

In a representative preclinical study, the RKO xenograft model was successfully established in immunodeficient mice to evaluate novel therapeutic candidates targeting the MSI-H molecular subtype of colon cancer. Tumors demonstrated consistent engraftment rates and progressive growth kinetics, with treatment arms showing differential responses in tumor growth inhibition and survival endpoints. Comprehensive histopathological and molecular analyses revealed modulation of key signaling pathways, including p53-mediated apoptosis and DNA damage response markers. Detailed quantitative data, including tumor growth curves, survival analysis, and biomarker expression profiles, are available upon request. Please contact our team to discuss how these findings can inform your specific drug development program.

Why Choose Alfa Cytology?

Alfa Cytology combines scientific rigor with operational flexibility to deliver high-quality RKO xenograft services that meet the demands of modern preclinical oncology research. Our integrated approach ensures seamless execution from study design to data delivery.

• Validated RKO cell lines with confirmed STR profiles and documented MSI-H, wild-type TP53, and MLH1 silencing status.
• Standardized xenograft workflows optimized for both subcutaneous and orthotopic implantation, ensuring high engraftment success and reproducible tumor growth kinetics.
• IACUC-compliant and GLP-aligned study execution with comprehensive tumor monitoring, body weight tracking, and humane endpoint management.
• Multi-endpoint analysis capabilities including histopathology (H&E, IHC), molecular profiling (RT-qPCR, Western blot, proteomics), and biomarker quantification.
• Customizable study designs accommodating combination therapies, dose-response evaluations, pharmacokinetic assessments, and mechanism-of-action investigations.
• Dedicated project management with rapid turnaround times, transparent communication, and detailed reporting to support regulatory filings and publication requirements.

Contact Us

Ready to advance your colon cancer therapeutic program with a validated RKO xenograft model? Contact us today to discuss your study requirements and receive a customized proposal. Our team is prepared to support your preclinical research from initial model construction through comprehensive endpoint analysis. Reach out to us now and let Alfa Cytology be your trusted partner in accelerating oncology drug development.

For research use only. Not intended for any clinical use.